Patients taking aripiprazole 400 mg once monthly for maintenance treatment of bipolar I disorder experienced only time-limited adverse events, supporting the idea that once-monthly aripiprazole 400 mg is a well-tolerated treatment, according to results published in the Journal of Affective Disorders.

Prior studies of aripiprazole once-monthly 400 mg have demonstrated its efficacy and safety for the maintenance treatment of bipolar disorder I.

The study included participants with bipolar disorder I who were stabilized on oral aripiprazole for 2 to 8 weeks and then switched to aripiprazole once-monthly 400 mg (12-28 weeks). Participants who met stability criteria were then randomly assigned to continued aripiprazole once-monthly 400 mg (n=133) or placebo (n=133) up to week 52. The researchers collected data on treatment-emergent adverse events. They also performed a separate analysis on new-onset akathisia.

The most prevalent treatment-emergent adverse events were akathisia, which occurred in 23.3% of participants, and weight gain, which occurred in 10.6% of participants.


Continue Reading

The median time to onset of akathisia was 20 days after starting aripiprazole, and the median duration was 29 days for the first occurrence. Of participants who reported akathisia, 12.5% (21/168) experienced >1 episode. The prevalence of new-onset akathisia decreased over time.

Related Articles

Most participants who experienced weight gain reported that it started within 3 months after their first aripiprazole once-monthly 400-mg injection, rather than with oral aripiprazole. Weight gain tended to plateau at 36 weeks, with a mean weight gain of ≤1.0 kg.

“Knowing the temporal patterns of [adverse events] can help the clinicians and patients in setting expectations for the treatment, thus informing clinical decision-making,” the researchers wrote.

Disclosure

This research was supported by H. Lundbeck A/S and Otsuka Pharmaceutical Development & Commercialization, Inc.

Reference

Calabrese JR, Sanchez R, Jin N, et al. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder. a double-blind, placebo-controlled randomized withdrawal study. J Affect Disord. 2018;241:425-432.